[ad_1]
doi: 10.1007/978-981-16-8702-0_9.
Affiliations
Affiliations
- 1 Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China.
- 2 Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China. kyyuen@hku.hk.
Item in Clipboard
Hanjun Zhao et al.
Adv Exp Med Biol.
2022.
Display options
Format
doi: 10.1007/978-981-16-8702-0_9.
Affiliations
- 1 Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China.
- 2 Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China. kyyuen@hku.hk.
Item in Clipboard
Display options
Format
Abstract
With the increasing global human population, travel, and socioeconomic activities, more and more novel pathogenic viruses will emerge or re-emerge. While more than 260 viruses are known to infect humans, only a small minority of these viral diseases are treatable by clinically approved antiviral drugs. Apart from these identified viruses, new emerging viruses and drug-resistant viruses are also important challenges to our public health and healthcare systems. The COVID-19 and influenza pandemics remind us the importance of getting broad-spectrum antivirals against emerging and re-emerging respiratory viruses. Broad-spectrum antivirals against different viral families for fighting the currently known viruses and novel emerging viruses are urgently needed. Viral entry is the universal first step for viral infection, and therefore is a promising target for identifying broad-spectrum antivirals. In this chapter, we mainly focus on discussing the risks of respiratory viruses, the challenge of finding broad-spectrum antivirals, the entry processes of respiratory viruses, the current studies on broad-spectrum entry inhibitors for respiratory viruses, and the directions for discovering broad-spectrum antivirals in the future.
Keywords:
Antiviral; Broad-spectrum; Entry inhibitor; Respiratory virus; Viral entry.
© 2022. Springer Nature Singapore Pte Ltd.
References
-
-
Anthony SJ, Epstein JH, Murray KA, Navarrete-Macias I, Zambrana-Torrelio CM, Solovyov A, Ojeda-Flores R, Arrigo NC, Islam A, Ali Khan S, Hosseini P, Bogich TL, Olival KJ, Sanchez-Leon MD, Karesh WB, Goldstein T, Luby SP, Morse SS, Mazet JA, Daszak P, Lipkin WI (2013) A strategy to estimate unknown viral diversity in mammals. MBio 4:e00598–e00513. https://doi.org/10.1128/mBio.00598-13
–
DOI
–
PubMed
–
PMC
-
-
-
Armero A, Berthet N, Avarre JC (2021) Intra-host diversity of SARS-Cov-2 should not be neglected: case of the state of Victoria, Australia. Viruses 13:133. https://doi.org/10.3390/v13010133
–
DOI
–
PubMed
–
PMC
-
-
-
Arnberg N, Pring-Akerblom P, Wadell G (2002) Adenovirus type 37 uses sialic acid as a cellular receptor on Chang C cells. J Virol 76:8834–8841. https://doi.org/10.1128/jvi.76.17.8834-8841.2002
–
DOI
–
PubMed
–
PMC
-
-
-
Arora P, Pöhlmann S, Hoffmann M (2021) Mutation D614G increases SARS-CoV-2 transmission. Signal Transduct Target Ther 6:101. https://doi.org/10.1038/s41392-021-00502-w
–
DOI
–
PubMed
–
PMC
-
-
-
Braga L, Ali H, Secco I, Chiavacci E, Neves G, Goldhill D, Penn R, Jimenez-Guardeño JM, Ortega-Prieto AM, Bussani R, Cannatà A, Rizzari G, Collesi C, Schneider E, Arosio D, Shah AM, Barclay WS, Malim MH, Burrone J, Giacca M (2021) Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia. Nature 594:88. https://doi.org/10.1038/s41586-021-03491-6
–
DOI
–
PubMed
–
PMC
-
Cite
[ad_2]
Source link
Trending Topics
Features
- Drive Toolkit
Download and distribute powerful vaccination QI resources for your community.
- Health Champions
Sign up now to support health equity and sustainable health outcomes in your community.
- Cancer Early Detection
MCED tests use a simple blood draw to screen for many kinds of cancer at once.
- PR
FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.
- Medicare
Discover an honest look at our Medicare system.
- Alliance for Representative Clinical Trials
ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.
- Reducing Patient Risk
The single most important purpose of our healthcare system is to reduce patient risk for an acute event.
- Jessica Wilson
- Jessica Wilson
- Victor Mejia
















